drugset
drugset / Trial / NCT04954781

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

NCT04954781 ↗

Phase 2 Recruiting 25 enrolled Fudan University
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of TACE combined with Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on first-line systemic therapy.

Timeline

Start
2021-07-14
Primary completion
2025-07-15
Completion
2025-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

intrahepatic cholangiocarcinoma